S621
Clinical – Head & neck
ESTRO 2026
Friedrichstadt, Dresden, Germany. 9 German Cancer Consortium (DKTK), Partner Site Berlin, and German Cancer Research Center (DKFZ), Heidelberg, Germany. 10 Department of Radiooncology and Radiotherapy, Charité, University Medicine, Berlin, Germany. 11 German Cancer Consortium (DKTK), Partner Site Essen, and German Cancer Research Center (DKFZ), Heidelberg, Germany. 12 Department of Radiotherapy, Medical Faculty, University of Duisburg-Essen, Essen, Germany. 13 German Cancer Consortium (DKTK), Partner Site Frankfurt, and German Cancer Research Center (DKFZ), Heidelberg, Germany. 14 Department of Radiotherapy and Oncology, Goethe-University, Frankfurt, Germany. 15 German Cancer Consortium (DKTK), Partner Site Freiburg, and German Cancer Research Center (DKFZ), Heidelberg, Germany. 16 Department of Radiation Oncology, Medical Center, Medical Faculty, University of Freiburg, Freiburg, Germany. 17 German Cancer Consortium (DKTK), Core Center Heidelberg, and German Cancer Research Center (DKFZ), Heidelberg, Germany. 18 Heidelberg Ion Therapy Center (HIT), Department of Radiation Oncology, University of Heidelberg Medical School, Heidelberg, Germany. 19 German Cancer Consortium (DKTK), Partner Site Munich, and German Cancer Research Center (DKFZ), Heidelberg, Germany. 20 Department of Radiotherapy and Radiation Oncology, University Hospital, Ludwig-Maximilians- Universität, Munich, Germany. 21 Department of RadioOncology, Technische Universität München, Munich, Germany. 22 German Cancer Consortium (DKTK), Partner Site Tübingen, and German Cancer Research Center (DKFZ), Heidelberg, Germany. 23 Department of Radiation Oncology, University Hospital Tübingen, Tübingen, Germany. 24 Institute of Pathology, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany. 25 German Cancer Research Center (DKFZ), Division of Radiooncology/Radiobiology, Heidelberg, Germany Purpose/Objective: In a previous retrospective multicentre study of the German Cancer Consortium - Radiation Oncology Group (DKTK-ROG) biomarker signatures for locoregional control (LRC) and overall survival (OS) were developed for patients with locally advanced head and neck squamous cell carcinoma (LA- HNSCC) [1]. The current prospective study aims to validate these signatures in the DKTK-ROG HNprädBio biomarker trial (NCT02059668). Material/Methods: For prospective (confirmatory) validation of the biomarker signatures 265 patients with LA-HNSCC were included. All patients received primary radiochemotherapy according to the HNprädBio study protocol between 2014 and 2020. Median follow-up
[Internet]. 2011 Apr [cited 2025 Nov 6];21(2):101–10.2. Dolezel M, Slavik M, Blazek T, Kazda T, Koranda P, Veverkova L, et al. FMISO-Based Adaptive Radiotherapy in Head and Neck Cancer. JPM [Internet]. 2022 July 29 [cited 2025 Nov 6];12(8):1245.3. Welz S, Paulsen F, Pfannenberg C, Reimold M, Reischl G, Nikolaou K, et al. Dose escalation to hypoxic subvolumes in head and neck cancer: A randomized phase II study using dynamic [18F]FMISO PET/CT. Radiotherapy and Oncology [Internet]. 2022 June [cited 2025 Nov 6];171:30–6. Keywords: Head and neck cancer, hypoxia, dose escalation Prospectively validated biomarker signature for personalized radiooncology: Results of the DKTK- ROG HNprädBio biomarker trial for primary RCT of HNSCC Annett Linge 1,2 , Steffen Löck 3,4 , Nadja Ebert 1,2 , Fabian Lohaus 1,2 , Dominik Haim 5,6 , Max Kemper 7,6 , Andreas Schreiber 8 , Ingeborg Tinhofer 9,10 , Goda Kalinauskaite 9,10 , Maja Guberina 11,12 , Martin Stuschke 11,12 , Maximilian Fleischmann 13,14 , Claus Rödel 13,14 , Henning Schäfer 15,16 , Anca-Ligia Grosu 15,16 , Thomas Held 17,18 , Jürgen Debus 17,18 , Claus Belka 19,20 , Steffi Pigorsch 19,21 , Stephanie E. Combs 19,21 , Simon Boeke 22,23 , Daniel Zips 9,10 , Gustavo B. Baretton 1,24 , Mechthild Krause 1,2 , Michael Baumann 17,25 1 German Cancer Consortium (DKTK), Partner Site Dresden, and German Cancer Research Center (DKFZ), Heidelberg, Germany. 2 Department of Radiotherapy and Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany. 3 OncoRay – National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Proffered Paper 3382 Technology, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany. 4 Helmholtz-Zentrum Dresden - Rossendorf, Institute of Radiooncology – OncoRay, Dresden, Germany. 5 Department of Oral and Maxillofacial Surgery, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany. 6 National Center for Tumor Diseases (NCT), NCT/UCC Dresden, a partnership between DKFZ, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, and Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany. 7 Department of Otorhinolaryngology, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany. 8 Department of Radiotherapy, Hospital Dresden-
Made with FlippingBook - Share PDF online